Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Chronic Myelomonocytic Leukemia (CMML)
Chemotherapy (chemo) is the use of certain types of drugs to treat cancer. The drugs can be swallowed as pills, or they can be injected into a vein or muscle. Chemo is considered systemic treatment because these drugs enter the bloodstream and reach most areas of the body.
This type of treatment is useful for chronic myelomonocytic leukemia (CMML), because the leukemia cells are not just in one part of the body. Chemo can help kill the leukemia cells in the bone marrow and allow normal ones to grow back.
Hydroxyurea is a chemo drug that can help some people with CMML live longer. This drug comes as a capsule that's taken by mouth, typically once or twice a day. It can bring the numbers of white blood cells, including monocytes, down to normal. It may also help shrink an enlarged spleen.
Because the main effect of hydroxyurea is to lower blood cell counts, anyone taking this drug will need to have their blood counts checked regularly. Other side effects are usually mild and can include mouth sores, skin rash or changes in color, and nail changes.
These drugs affect the way some genes inside cells are controlled. They activate some genes that help cells mature. They also kill cells that are dividing rapidly. This helps the normal bone marrow cells grow again, often leading to improved blood cell counts and the need for fewer transfusions.
Examples of this type of drug include:
These drugs are given as a shot under the skin or as an infusion into your blood (IV), often for several days in a row, followed by several weeks off.
A newer drug, known as Inqovi, combines decitabine with cedazuridine, which helps stop the decitabine from being broken down in the digestive system. This allows the drug to be taken by mouth as a tablet, typically once a day for 5 days in a row, which is repeated every 4 weeks.
Side effects of hypomethylating agents are usually mild and rarely lead to stopping treatment. Still, these drugs can have some of the same side effects as standard chemo drugs, including:
In the past, other chemo drugs have sometimes been used to treat CMML, especially if the drugs above are no longer working. This type of chemo might help a small number of people, but it can also have more serious side effects, which limits how useful it is, especially in people who are in poorer health. For people with CMML who are healthy enough, the goal is usually to have a stem cell transplant if it can be done, as it offers the best chance to cure it.
For more general information about how chemotherapy is used to treat cancer, see Chemotherapy.
To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Myelodysplastic Syndromes. Version 1.2024. Accessed at https://www.nccn.org on May 18, 2024.
Padron E. Chronic myelomonocytic leukemia: Management and prognosis. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/chronic-myelomonocytic-leukemia-management-and-prognosis on May 18, 2024.
Last Revised: May 21, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.